Lilly's Weekly Efsitora Alfa Insulin Delivers A1C Reduction Consistent With Daily Insulin
11/9 03:40
(RTTNews) - Eli Lilly and Co. (LLY) announced detailed results from the QWINT-2 phase 3 trial evaluating once-weekly insulin efsitora alfa (efsitora) compared to once-daily insulin degludec in adults with type 2 diabetes using insulin for the first time (insulin naive)....